Monte Rosa Therapeutics, Inc. (GLUE)
14.55
+0.78
(+5.63%)
USD |
NASDAQ |
Aug 25, 10:23
Monte Rosa Therapeutics Profit Margin (Quarterly) : -483.9% for June 30, 2026
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -483.9% |
| March 31, 2026 | -1.06K% |
| December 31, 2025 | -1.66K% |
| September 30, 2025 | -212.1% |
| June 30, 2025 | -53.01% |
| Date | Value |
|---|---|
| March 31, 2025 | 55.20% |
| December 31, 2024 | 22.16% |
| September 30, 2024 | -258.9% |
| June 30, 2024 | -645.6% |
| March 31, 2024 | -3.00K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Nurix Therapeutics, Inc. | -990.1% |
| Gilead Sciences, Inc. | -134.2% |
| Ironwood Pharmaceuticals, Inc. | 45.37% |
| Capricor Therapeutics, Inc. | -- |
| Cue Biopharma, Inc. | -1.94K% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -45.87% |
| Return on Assets | -29.88% |
| Return on Invested Capital | -41.23% |
| Gross Profit Margin (Quarterly) | 78.69% |
| Operating Margin (Quarterly) | -547.8% |
| Return on Net Operating Assets | -296.3% |